pI: 4.7009 |
Length (AA): 688 |
MW (Da): 79757 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_128172)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G18860 | transducin family protein / WD-40 repeat family protein |
Babesia bovis | BBOV_II004810 | WD domain, G-beta repeat containing protein |
Brugia malayi | Bm1_21170 | WD domain containing protein |
Candida albicans | CaO19.12292 | ubiquitin proteolysis |
Candida albicans | CaO19.4829 | ubiquitin proteolysis |
Caenorhabditis elegans | CELE_C05C10.6 | Protein UFD-3, isoform B |
Caenorhabditis elegans | CELE_C05C10.6a | Protein UFD-3, isoform C |
Cryptosporidium hominis | Chro.40262 | At3g18860/MCB22_3 |
Cryptosporidium parvum | cgd4_2320 | At3g18860/MCB22_3 |
Dictyostelium discoideum | DDB_G0291003 | hypothetical protein |
Drosophila melanogaster | Dmel_CG5105 | Phospholipase A2 activator protein |
Echinococcus granulosus | EgrG_000477800 | phospholipase A 2 activating protein |
Echinococcus multilocularis | EmuJ_000477800 | phospholipase A 2 activating protein |
Homo sapiens | ENSG00000137055 | phospholipase A2-activating protein |
Leishmania braziliensis | LbrM.24.1970 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_241970.1 | WD domain, G-beta repeat/PFU (PLAA family ubiquitin binding), putative |
Leishmania infantum | LinJ.24.1970 | hypothetical protein, conserved |
Leishmania major | LmjF.24.1900 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.24.1900 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_13163 | hypothetical protein |
Loa Loa (eye worm) | LOAG_05630 | WD domain-containing protein |
Mus musculus | 18786 | phospholipase A2, activating protein |
Neospora caninum | NCLIV_040730 | hypothetical protein |
Oryza sativa | 4342300 | Os07g0123700 |
Plasmodium berghei | PBANKA_1139400 | polyubiquitin binding protein, putative |
Plasmodium falciparum | PF3D7_1363400 | polyubiquitin binding protein, putative |
Plasmodium knowlesi | PKNH_1107900 | polyubiquitin binding protein, putative |
Plasmodium yoelii | PY05801 | Arabidopsis thaliana At3g18860/MCB22_3 |
Saccharomyces cerevisiae | YKL213C | Doa1p |
Schistosoma japonicum | Sjp_0129740 | Phospholipase A-2-activating protein, putative |
Schistosoma mansoni | Smp_017750 | phospholipase A-2-activating protein |
Schmidtea mediterranea | mk4.001405.12 | |
Schmidtea mediterranea | mk4.002121.09 | |
Schmidtea mediterranea | mk4.001405.13 | Phospholipase A-2-activating protein |
Schmidtea mediterranea | mk4.002121.10 | Phospholipase A-2-activating protein |
Trypanosoma brucei gambiense | Tbg972.8.6390 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.8.6330 | WD domain, G-beta repeat/PFU (PLAA family ubiquitin binding), putative |
Trypanosoma congolense | TcIL3000_0_44870 | PFU (PLAA family ubiquitin binding), putative |
Trypanosoma cruzi | TcCLB.503885.90 | WD domain, G-beta repeat/PFU (PLAA family ubiquitin binding), putative |
Trypanosoma cruzi | TcCLB.511903.290 | WD domain, G-beta repeat/PFU (PLAA family ubiquitin binding), putative |
Toxoplasma gondii | TGME49_288210 | PUL domain-containing protein |
Theileria parva | TP02_0270 | hypothetical protein |
Trichomonas vaginalis | TVAG_358850 | phospholipase A-2-activating protein, putative |
Trichomonas vaginalis | TVAG_287800 | phospholipase A-2-activating protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.6330 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.6330 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.6330 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.8.6330 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C05C10.6 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C05C10.6 | Caenorhabditis elegans | slow growth | wormbase |
TGME49_288210 | Toxoplasma gondii | Probably essential | sidik |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | phospholipase A2-activating protein | Compounds | References |